期刊文献+

CD59遗传变异与冠心病无相关性

CD59 Polymorphisms Are Not Associated with Coronary Artery Disease in Chinese Population
原文传递
导出
摘要 目的 CD59参与免疫、动脉粥样硬化等过程,CD59遗传变异是否与冠心病、慢性心肌梗塞相关研究甚少。我们探索在CD59启动子区、内含子区、编码区和3’非翻译区域的遗传变异与冠心病相关性,推断CD59在冠心病发生发展中的作用。方法根据生物信息学分析结果,我们选取了CD59的7个单核苷酸多态性(SNP)rs7046,rs831603,rs831600,rs704700,rs1718067,rs1047581,和rs77450648。在病例对照研究中,入选对照661例,非心梗冠心病661例,慢性心梗626例,使用MassARRAY高通量DNA飞行时间质谱法进行基因分型,基因分型结果经测序来进一步验证。利用SPSS软件进行统计学分析。结果非心梗冠心病组、慢性心梗组和对照组均存在CD59的其中6个SNPs,基因型频率分布符合Hardy—Weinberg平衡。非心梗冠心病和慢性心梗病例组与对照组CD59的6个单核苷酸多态性的基因型频率和等位基因频率无显著性差异。结论 CD59遗传变异与非心梗冠心病和慢性心肌梗塞无显著相关性。 Objective CD59 is involved in immunity, atherosclerosis, but little is known regarding the association of CD59 genetic variants with coronary artery disease (CAD). Our aim is to determine the association of CD59 tagged genetic variants with 2 types of coronary artery disease, including non-myocardial infarction (Ml) CAD and chronic MI, and conclude the role of CD59 involved in CAD. Methods In a case-control study, the rs7046, rs831603, rs831600, rs704700, rs1718067, rs1047581, and rs77450648 polymorphisms were selected to analyze after in silico analysis. Total 661 patients with non-MI CAD, 626 patients with chronic MI and 661 controls were recruited. Genotyping was performed by using MassAR- RAY high-throughput DNA analysis with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Reproducibility of genotyping was confirmed by bidirectional sequencing in 500 samples and the reproducibility was 99.4%. Statistical analysis was performed using SPSS 13.0 software. Results In non-M1 CAD, chronic MI groups and the control group, only rs77450648 was not observed, and the frequency distribution of the other polymorphisms fulfilled with the Hardy-Weinberg equilibrium. No association was observed between the 6 SNPs and non-Ml CAD or chronic MI. Conclusion CD59 SNPs were not associated with CAD.
出处 《中国分子心脏病学杂志》 CAS 2013年第2期493-496,共4页 Molecular Cardiology of China
基金 国家自然科学基金31171220 协和新星计划2011XH05 中央高校基本科研业务费专项资金2012Y04
关键词 CD59 单核苷酸多态性 非心梗冠心病 慢性心肌梗塞 CD59 SNP Coronary Artery Disease Chronic Myocardial Infarction
  • 相关文献

参考文献15

  • 1Haskard DO, Boyle JJ, Mason IC. The role of complement in atherosclerosis. Curr Opin Lipidol. 2008 Oct; 19(5):478-82.
  • 2Ruth D. Lewis, Christopher L. Jackson, B. Paul Morgan, et al.The membrane attack complex of complement drives the progression of atherosclerosis in apolipoprotein E knockout mice I Mol Immunol. 2010 February; 47(5): 1098-1105.
  • 3Niculescu F, Rus H .. Complement activation and atherosclerosis. Mol Immunol. 1999 Sep-Oct;36(13-14):949-55.
  • 4Gorter A, Meri S. Immune evasion of tumor cells using membrane-bound complement regulatory proteins.lmmunol Today. 1999 Dec;20(12):576- 82.
  • 5Meri S, Morgan BP, Davies A, et al.Human protectin (CD59), an 18,000- 20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion ofC9 into lipid bilayers.lmmunology. 1990 Sep;71(1):1-9.
  • 6Tada T, Okada H, Okada N, et al.Membrane attack complex of complement and 20 kDa homologous restriction factor (CD59) in myocardial infarction. l'irchows Arch. 1997 Apr;430(4):327-32.
  • 7Lu JG, Lv B, Chen XB, et al. What is the best contrast injection protocol for 64-row multi-detector cardiac computed tomography? Eur J Rodiol 2010;75: 159-65.
  • 8Sarah E. Calvo, David J. Pagliarini , et al.Upstream open reading frames cause widespread reduction of protein expression and are polymorphic among humans. PNAS, May 5, 2009,106 (18) : 7507-7512.
  • 9朱芙丽,刘永铭.CD55和CD59表达的调节因素和调节机制的研究进展[J].中国免疫学杂志,2008,24(11):1049-1053. 被引量:4
  • 10刘永铭,严祥,刘艳英.补体与动脉粥样硬化[J].中华心血管病杂志,2005,33(9):866-869. 被引量:21

二级参考文献69

  • 1Cheng Zhang Chun-Lin Ge Ren-Xuan Guo San-Guang He.Effect of IL-4 on altered expression of complement activation regulators in rat pancreatic cells during severe acute pancreatitis[J].World Journal of Gastroenterology,2005,11(43):6770-6774. 被引量:14
  • 2Speidl W S, Exner M, Amighi J et al. Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis [ J]. Eur Heart J, 2005 ;26(21 ) :2294-2299.
  • 3Chan R K, Ibrahim S I, Takahashi K et al. the differing roles of the classical and mannose-binding lectin complement pathways in the events following skeletal muscle ischemia-reperfusion [J]. J Immunol, 2006; 177 ( 11 ) : 8080-8085.
  • 4Vasil K E, Magro C M. Cutaneous vascular deposition of C5b-9 and its role as a diagnostic adjunct in the setting of diabetes mellitus and porphyria cutanea tarda[J] .J Am Acad Dermatol,2007;56(1):96-104.
  • 5Biro E, Nieuwland R, Tak P P et al. Activated complement components and complement activatomolectdes on the surface of cell-derived microparticles in patients with rheumatoid arthritis and healthy individuals [J] .Ann Rheum Dis,2007;66(8): 1085-1092.
  • 6Woodruff T M, Pollitt S, Proctor L Met al. Increased potency of a novel complement factor 5a receptor antagonist in a rat model of inflammatory bowel disease[J] .J Pharmacol Exp Ther,2005;314(2) :811-817.
  • 7Trouw L A,Seelen M A,Duijs J M et al.Activation of the lecfin pathway in murine lupus nephritis[J]. Mol Immunol,2005 ;42(6):731-734.
  • 8Justin C Mason, Helen Yarwood, Katharine Sugars et al. Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition[ J]. Blood, 1999;94(5) : 1673-1682.
  • 9Saifur R A, Elaine A L, Riedo Ohta et al. Decay-accelerating factor induction by tumoumecrosis factor-α, through a phosphatidylinositol-3 kinase and protein kinase C-dependentpathway, protects murine vascular endothelial cells against complement deposition [ J ]. Immunology, 2003 ; 110 : 258- 268.
  • 10Spiller O Criado-Garciaa, S Rodriatguez De Coardoba, Morgan B P. Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma ceils from complement attack [ J ]. Clin Exp I mmunol, 2000; 121: 234-241.

共引文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部